Results 71 to 80 of about 4,636,683 (298)

Current Status of Self-transcendence among Lung Cancer Patients 
and Its Influencing Factors

Chinese Journal of Lung Cancer
Background and objective Different degrees of self-transcendence exist in lung cancer patients, which can stimulate patients' self-awareness and promote them to face negative events in life positively, thus improving patients' quality of life and ...
Xue YANG, Yu LUO, Lijuan YE, Yingli YU, Daxing ZHU   +4 more
doaj   +1 more source

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids

Chinese Journal of Lung Cancer, 2016
Background and objective The incidence of pulmonary carcinoid (PC) is very rare in primary lung malignant tumors, and the prognosis of this disease is closely associated with its pathological features. In this study, the expressions of programmed death 1
Mingbiao LI, Song XU, Haiyang FAN, Hongyi ZHANG, Ying LI, Yongwen LI, Minghui LIU, Hongyu LIU, Jun CHEN   +8 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Lost in the Vaso‐Occlusion: A Patient's Abdominal Pain Returns With a Vengeance

Pediatric Blood &Cancer, EarlyView.
Dunia Hatabah, Martha E. Stewart, Nathan Maassel, James P. Stevens, Claudia R. Morris, Chris A. Rees   +5 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Role of dietary carbohydrates on risk of lung cancer

, 2021
Objectives: Inconsistent findings have been reported on the link between dietary carbohydrates and lung cancer. This study aims to comprehensively evaluate the role of dietary carbohydrates on lung cancer risk. Materials and methods: The prospective
Wang, X, Jatoi, A, Crawford, J, Lam, WWT, Ho, JC, TAO, J, Pang, H   +6 more
core   +1 more source

Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis

BMC Cancer
Background This network meta-analysis (NMA) aimed to indicate the most effective first-line therapeutic options for advanced EGFR-mutated NSCLC, particularly considering their specific clinicopathological characteristics.
Ting Mei, Ting Wang, Qinghua Zhou
doaj   +1 more source

Ensartinib as a neoadjuvant therapy for stage IIIA non-small cell lung cancer patients with EML4-ALK fusion: a case report and literature review

Frontiers in Oncology
Anaplastic lymphoma kinase (ALK) inhibitors have shown efficacy in treating ALK-positive advanced non-small cell lung cancer (NSCLC) patients. However, the effectiveness of ensartinib neoadjuvant therapy remains ambiguous.
Hao Zhang, Hao Zhang, Wei Xia, Wei Xia, Yifan Zhang, Yifan Zhang, Shihao Bao, Shihao Bao, Jingtong Zeng, Jingtong Zeng, Xianjie Li, Xianjie Li, Bo Zhang, Bo Zhang, Hanqing Wang, Hanqing Wang, Song Xu, Song Xu, Zuoqing Song, Zuoqing Song   +19 more
doaj   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source